A Setback In Its High-Profile “Nuc” Trial Creates An Overhang For Gilead’s HCV Pipeline
This article was originally published in The Pink Sheet Daily
Executive Summary
Gilead concedes that 12 weeks of treatment with ribavirin and GS-7977, the high-profile “nuc” asset it obtained when it bought Pharmasset late in 2011 is suboptimal for genotype 1 null responders; general expectation is that longer duration of therapy might suffice.